Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Target Price at $6.75

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have received an average rating of “Moderate Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $11.80.

Several brokerages have recently commented on CMPX. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research note on Monday, November 11th. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $5.00 to $4.00 in a report on Friday, November 15th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Monday, September 16th. D. Boral Capital assumed coverage on shares of Compass Therapeutics in a research note on Monday, December 23rd. They issued a “buy” rating and a $32.00 target price for the company. Finally, Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th.

Compass Therapeutics Stock Down 3.9 %

Shares of NASDAQ:CMPX opened at $1.46 on Monday. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34. The stock’s 50 day moving average is $1.60 and its 200-day moving average is $1.42. The firm has a market capitalization of $200.88 million, a price-to-earnings ratio of -3.95 and a beta of 0.89.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Equities research analysts anticipate that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds have recently modified their holdings of the stock. Rovin Capital UT ADV bought a new position in Compass Therapeutics in the 3rd quarter worth approximately $25,000. Intech Investment Management LLC purchased a new stake in shares of Compass Therapeutics during the third quarter worth $30,000. XTX Topco Ltd bought a new position in shares of Compass Therapeutics in the third quarter worth $37,000. SG Americas Securities LLC grew its position in shares of Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after purchasing an additional 5,515 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Compass Therapeutics during the 2nd quarter valued at $41,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.